Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Company expects strong organic growth in sales, EBITDA in 2022
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Subscribe To Our Newsletter & Stay Updated
